文献速递呼吸道感染呼吸危重症与机械通气

法国多中心MYCOVID研究:首波新冠机械通气患者侵袭性真菌感染情况

Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study.
PubMed 文献 · Lancet Respir Med · 2021-11-26

本研究为法国18个ICU的多中心观察性队列研究,纳入565例机械通气新冠患者,分析其中至少三次真菌筛查的509例。

要点

  • 机械通气新冠患者中侵袭性真菌感染患病率高达25%,其中CAPA占15%。
  • 年龄>62岁、使用地塞米松联合抗IL-6、机械通气>14天是CAPA独立危险因素。

核心结论

  • 机械通气新冠患者中侵袭性肺曲霉病和念珠菌血症患病率高,确诊/临床诊断CAPA与ICU死亡率显著增加相关。

研究设计与样本

  • 法国18个ICU开展的国家级多中心观察性队列研究,纳入565例机械通气新冠患者,其中509例至少三次真菌筛查者纳入分析。

主要发现

  • 128例(25%)患者发生138次确诊/临床诊断或可能侵袭性真菌感染,76例(15%)符合确诊/临床诊断CAPA。
  • 38例(7%)发生其他确诊/临床诊断侵袭性真菌感染:32例(6%)念珠菌血症,6例(1%)侵袭性毛霉病,1例(<1%)侵袭性镰刀菌病。

关键数值与推荐

  • 确诊/临床诊断CAPA依据ECMM/ISHAM最新定义分类。
  • 主要结局为至少三次微生物学筛查的合格受试者中侵袭性真菌感染患病率。

临床怎么用

  • 对机械通气新冠患者应积极进行真菌病原体主动监测,尤其年龄>62岁、接受地塞米松联合抗IL-6治疗或机械通气>14天者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with severe COVID-19 have emerged as a population at high risk of invasive fungal infections (IFIs). However, to our knowledge, the prevalence of IFIs has not yet been assessed in large populations of mechanically ventilated patients. We aimed to identify the prevalence, risk factors, and mortality associated with IFIs in mechanically ventilated patients with COVID-19 under intensive care. METHODS: We performed a national, multicentre, observational cohort study in 18 French intensive care units (ICUs). We retrospectively and prospectively enrolled adult patients (aged ≥18 years) with RT-PCR-confirmed SARS-CoV-2 infection and requiring mechanical ventilation for acute respiratory distress syndrome, with all demographic and clinical and biological follow-up data anonymised and collected from electronic case report forms. Patients were systematically screened for respiratory fungal microorganisms once or twice a week during the period of mechanical ventilation up to ICU discharge. The primary outcome was the prevalence of IFIs in all eligible participants with a minimum of three microbiological samples screened during ICU admission, with proven or probable (pr/pb) COVID-19-associated pulmonary aspergillosis (CAPA) classified according to the recent ECMM/ISHAM definitions. Secondary outcomes were risk factors of pr/pb CAPA, ICU mortality between the pr/pb CAPA and non-pr/pb CAPA groups, and associations of pr/pb CAPA and related variables with ICU mortality, identified by regression models. The MYCOVID study is registered with ClinicalTrials.gov, NCT04368221. FINDINGS: Between Feb 29 and July 9, 2020, we enrolled 565 mechanically ventilated patients with COVID-19. 509 patients with at least three screening samples were analysed (mean age 59·4 years [SD 12·5], 400 [79%] men). 128 (25%) patients had 138 episodes of pr/pb or possible IFIs. 76 (15%) patients fulfilled the criteria for pr/pb CAPA. According to multivariate analysis, age older than 62 years (odds ratio [OR] 2·34 [95% CI 1·39-3·92], p=0·0013), treatment with dexamethasone and anti-IL-6 (OR 2·71 [1·12-6·56], p=0·027), and long duration of mechanical ventilation (>14 days; OR 2·16 [1·14-4·09], p=0·019) were independently associated with pr/pb CAPA. 38 (7%) patients had one or more other pr/pb IFIs: 32 (6%) had candidaemia, six (1%) had invasive mucormycosis, and one (<1%) had invasive fusariosis. Multivariate analysis of associations with death, adjusted for candidaemia, for the 509 patients identified three significant factors: age older than 62 years (hazard ratio [HR] 1·71 [95% CI 1·26-2·32], p=0·0005), solid organ transplantation (HR 2·46 [1·53-3·95], p=0·0002), and pr/pb CAPA (HR 1·45 [95% CI 1·03-2·03], p=0·033). At time of ICU discharge, survival curves showed that overall ICU mortality was significantly higher in patients with pr/pb CAPA than in those without, at 61·8% (95% CI 50·0-72·8) versus 32·1% (27·7-36·7; p<0·0001). INTERPRETATION: This study shows the high prevalence of invasive pulmonary aspergillosis and candidaemia and high mortality associated with pr/pb CAPA in mechanically ventilated patients with COVID-19. These findings highlight the need for active surveillance of fungal pathogens in patients with severe COVID-19. FUNDING: Pfizer.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Gangneux JP, Dannaoui E, Fekkar A, et al. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respir Med. 2021. PMID: 34843666. doi:10.1016/S2213-2600(21)00442-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。